What is Enhanc3D Genomics?
Enhanc3D Genomics is a specialized spinout originating from the Babraham Institute in Cambridge, UK. Founded by preeminent academic scientists, the company operates at the intersection of regulatory genomics and chromosomal architecture. By mapping the 3D structure of the genome, the firm provides critical insights into gene regulation, which is essential for identifying novel therapeutic targets. Its presence on the Cambridge BioMedical Campus places it at the heart of a global innovation hub, allowing for seamless collaboration with leading research institutions and industry partners. The company's platform is designed to translate complex genomic data into actionable insights, addressing significant unmet needs in drug discovery and precision medicine.
How much funding has Enhanc3D Genomics raised?
Enhanc3D Genomics has raised a total of $30.3M across 2 funding rounds:
Series A
$11.3M
Series A
$19M
Series A (2022): $11.3M with participation from Bioqube Ventures, Parkwalk Advisors, and BGF
Series A (2025): $19M led by BGF, Parkwalk Advisors, and Meltwind Advisory
Key Investors in Enhanc3D Genomics
BGF
BGF is a prominent UK-based investor focused on supporting the growth of small and mid-sized businesses across diverse economic sectors.
Parkwalk Advisors
Parkwalk Advisors specializes in bridging the gap between academic research and commercial success, with a strong focus on university spinouts in the deeptech and healthtech sectors.
Meltwind Advisory
Meltwind Advisory provides strategic guidance and capital to early-stage biotech and life science companies, with a focus on platform therapeutics and life science tools.
What's next for Enhanc3D Genomics?
With the recent capital deployment, Enhanc3D Genomics is expected to transition from its foundational research phase into a more aggressive commercialization and clinical development stage. The strategic focus will likely center on scaling its proprietary technology platform to support broader drug discovery pipelines and enhancing its internal capabilities in data-driven health. As the company continues to mature, the focus will shift toward establishing key partnerships with pharmaceutical entities and advancing its lead candidates through early clinical milestones. This strategic roadmap is designed to solidify the company's market position as a leader in the application of 3D genomic insights to solve complex medical challenges, ultimately driving long-term value for stakeholders and patients alike.
See full Enhanc3D Genomics company page
